Here’s why Deutsche Bank is upbeat on pharmaceutical sector
moneycontrol.com | February 23, 2017
Deutsche Bank is hopeful of better health of pharma stocks going forward due to easing regulatory concerns as well as actions by the US Food and Drug Administration (FDA). The brokerage remains constructive on stocks with superior earnings growth trajectory and strong execution track record. “We forecast the sector to post an 18% CAGR in FY16- 18 (20% CAGR over FY13-16), led by Sun Pharmaceuticals (32%), Aurobindo Pharma (21%) and Glenmark (45%),” the report said. Its top bets are Aurobindo and Sun Pharma, while it has a sell call on Dr. Reddy’s